{"id":"NCT03597464","sponsor":"Aurinia Pharmaceuticals Inc.","briefTitle":"Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin","officialTitle":"A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Voclosporin (23.7 mg Twice Daily) With Placebo in Subjects With Lupus Nephritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-29","primaryCompletion":"2021-10-07","completion":"2021-10-07","firstPosted":"2018-07-24","resultsPosted":"2022-12-14","lastUpdate":"2022-12-14"},"enrollment":216,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lupus Nephritis"],"interventions":[{"type":"DRUG","name":"Voclosporin","otherNames":["ISA247"]},{"type":"DRUG","name":"Placebo Oral Capsule","otherNames":[]}],"arms":[{"label":"Voclosporin","type":"EXPERIMENTAL"},{"label":"Placebo Oral Capsule","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus nephritis (LN).","primaryOutcome":{"measure":"Adverse Events (AE) Profile and Routine Biochemical and Hematological Assessments.","timeFrame":"Month 12 (AURORA 2 baseline) to Month 36","effectByArm":[{"arm":"Voclosporin","deltaMin":100,"sd":null},{"arm":"Placebo Oral Capsule","deltaMin":80,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["22879439","22087680","24330024","23996158","23736966","21943027","37528520"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":116},"commonTop":["Urinary tract infection","Hypertension","Glomerular filtration rate decreased","Diarrhoea","Viral upper respiratory tract infection"]}}